IL-23p40 specific antibody
US7247711B2 · kind B2 · utility
56Cited by
7References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2004 |
| Grant date | Jul 24, 2007 |
| Priority date | — |
| Expiry date | Oct 7, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.